Press release
Pleural Diseases Market Expected to Grow to USD 9.2 Billion by 2034
Pleural Diseases
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71497
The pleural diseases market is experiencing significant growth due to advancements in diagnostic technologies, targeted therapies, and early intervention strategies. The increasing incidence of pleural diseases, particularly mesothelioma, combined with advancements in personalized medicine and non-invasive diagnostic tools, is expected to drive continued market expansion through 2034.
Market Overview
• Market Size (2024): USD 5.8 billion
• Forecast (2034): USD 9.2 billion
• CAGR (2025-2034): ~5.1%
• Key Growth Drivers: Increasing prevalence of pleural diseases, advancements in diagnostic imaging, personalized therapies, and growing awareness of pleural diseases.
• Key Challenges: High treatment costs, late diagnosis, and limited access to specialized treatments, particularly in low-resource settings.
• Leading Players: Pfizer, Roche, Novartis, Boehringer Ingelheim, Merck & Co., Bristol Myers Squibb, and AstraZeneca.
Segmentation Analysis
By Therapy Type
• Chemotherapy (for pleural mesothelioma)
• Immunotherapy (targeted therapies, immune checkpoint inhibitors like nivolumab, pembrolizumab)
• Pleurodesis (to treat pleural effusion)
• Surgical Treatment (e.g., pleurectomy, decortication)
• Oxygen Therapy (for pleural effusion-induced respiratory distress)
• Anti-Inflammatory Agents (corticosteroids, non-steroidal anti-inflammatory drugs [NSAIDs])
By Route of Administration
• Oral
• Injectable (intravenous, subcutaneous)
• Inhaled (for aerosolized therapies)
By End Use
• Hospitals (oncology departments, pulmonary units)
• Specialized Cancer Centers (for mesothelioma treatments)
• Outpatient Clinics
• Homecare
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Summary: Chemotherapy and immunotherapies are the most common treatments for pleural mesothelioma, while pleurodesis and oxygen therapy are used to treat pleural effusion.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71497/pleural-diseases-market
Regional Analysis
• North America: Largest market share, driven by high mesothelioma incidence, strong healthcare infrastructure, and significant investments in cancer research.
• Europe: Significant market growth, particularly in Germany, the UK, and France, where pleural effusion management and mesothelioma treatments are well-established.
• Asia-Pacific: Fastest-growing region, with rising air pollution, increasing smoking rates, and improving healthcare access in countries like China, Japan, and India.
• Middle East & Africa: Moderate growth, with increasing healthcare investments and growing adoption of cancer therapies in GCC countries.
• Latin America: Brazil and Mexico lead regional growth, with rising awareness of pleural diseases and expanding oncology care.
Summary: North America and Europe dominate in terms of market value, but Asia-Pacific is expected to post the highest CAGR (~9%) through 2034, driven by rising disease burden and improved healthcare systems.
Market Dynamics
Key Growth Drivers
• Increasing incidence of pleural diseases, particularly mesothelioma, due to asbestos exposure, smoking, and lung cancer.
• Advancements in diagnostic imaging such as CT scans, MRI, and ultrasound, enabling early detection and accurate diagnosis of pleural diseases.
• Immunotherapies and targeted therapies emerging as effective treatments for mesothelioma and pleural effusion, offering better patient outcomes.
• Growing awareness of pleural diseases and early intervention, especially in regions with high levels of industrial pollution and asbestos exposure.
Key Challenges
• High treatment costs, especially for chemotherapy, immunotherapies, and targeted treatments, limiting patient access to effective therapies.
• Late diagnosis and difficulty in distinguishing pleural diseases from other lung conditions, leading to delayed treatment.
• Limited access to specialized care in rural and low-resource areas, contributing to poor outcomes in many patients.
Latest Trends
• The growing use of immune checkpoint inhibitors like nivolumab and pembrolizumab for pleural mesothelioma and other pleural diseases, enhancing treatment efficacy.
• Non-invasive therapies like pleurodesis gaining popularity for managing pleural effusion and reducing the need for invasive surgical procedures.
• Increasing adoption of targeted therapies based on genetic profiling, allowing for personalized treatment plans that improve outcomes.
• Integration of digital health tools for remote monitoring, improving patient compliance and management of pleural diseases outside the hospital setting.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71497
Competitor Analysis
Major Players
• Pfizer - Leading in the development of immunotherapies like Pembrolizumab (Keytruda), which is gaining approval for pleural mesothelioma and other lung cancers.
• Roche - Innovating in immunotherapies and targeted therapies for pleural mesothelioma and pleural effusion.
• Novartis - Focused on oncology treatments for pleural diseases, including targeted therapies and chemotherapies.
• Boehringer Ingelheim - Active in cancer research and inflammatory lung diseases, with treatments for mesothelioma and other pulmonary conditions.
• Merck & Co. - Known for its immunotherapies like Keytruda and antibody-based treatments in oncology.
• AstraZeneca - Developing immunotherapies and targeted treatments for pleural diseases, with products like Imfinzi for lung cancer and mesothelioma.
• Sanofi - Expanding in cancer immunotherapies, focusing on mesothelioma and pleural effusion treatments.
• Teva Pharmaceuticals - Known for its generic therapies and respiratory treatments, providing affordable options for pleural diseases.
Summary: The pleural diseases market is dominated by Pfizer, Roche, and Merck & Co., with increasing competition from Boehringer Ingelheim, Novartis, and AstraZeneca in the field of immunotherapies and targeted treatments.
Conclusion
The pleural diseases market is set for strong growth, driven by advancements in diagnostic imaging, immunotherapies, and targeted treatments. With a projected CAGR of ~5.1% (2025-2034), the market is poised for significant expansion, though challenges related to high treatment costs and delayed diagnosis persist.
Key Takeaways:
• Immunotherapies and chemotherapies remain central to the treatment of pleural mesothelioma and pleural effusion, with targeted therapies showing great promise.
• Asia-Pacific will experience the highest growth due to increasing industrial pollution and growing healthcare access.
• Biosimilars, combination therapies, and personalized medicine will enhance treatment outcomes and patient access.
• Companies focusing on oncology research, immunotherapies, and personalized care will lead the market.
The future of pleural disease management promises better early diagnosis, advanced treatments, and greater patient access, positioning the pleural diseases market as a key growth segment in oncology and respiratory care.
This report is also available in the following languages : Japanese (胸膜疾患市場), Korean (흉막 질환 시장), Chinese (胸膜疾病市场), French (Marché des maladies pleurales), German (Markt für Pleuraerkrankungen), and Italian (Mercato delle malattie pleuriche), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @https://exactitudeconsultancy.com/reports/71497/pleural-diseases-market#request-a-sample
Our More Reports:
Malignant Pleural Effusion Market
https://exactitudeconsultancy.com/reports/71507/malignant-pleural-effusion-market
Chronic Refractory Cough Market
https://exactitudeconsultancy.com/reports/71505/chronic-refractory-cough-market
Reactive Airway Disease Market
https://exactitudeconsultancy.com/reports/71503/reactive-airway-disease-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pleural Diseases Market Expected to Grow to USD 9.2 Billion by 2034 here
News-ID: 4168125 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for Pleural
Pleural Effusion Market Emerging Trends and Growth Prospects 2034
Introduction
Pleural effusion, a condition characterized by the accumulation of excess fluid in the pleural cavity, often results from underlying diseases such as malignant tumors, heart failure, and infections. This condition can significantly impair respiratory function and lead to symptoms like shortness of breath, chest pain, and coughing. The global burden of pleural effusion is rising, particularly due to the increasing prevalence of lung cancer, heart disease, and chronic respiratory diseases.
The…
Malignant Pleural Effusion Pipeline Therapeutics Assessment Report 2024 (Updated …
DelveInsight's, "Malignant Pleural Effusion Pipeline Insight 2024" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Malignant Pleural Effusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Malignant Pleural Effusion Research.…
Pleural Drainage Catheters Market Size 2024 to 2031.
Market Overview and Report Coverage
A Pleural Drainage Catheter is a medical device used to drain fluid or air from the pleural cavity surrounding the lungs. These catheters are commonly used in patients suffering from conditions such as pneumonia, lung cancer, or pleural effusion.
The Pleural Drainage Catheters Market is expected to witness significant growth in the coming years, with a projected CAGR of 7.80% during the forecasted period. This…
Pleural Drainage Catheters Market Will Generate Record Revenue by 2031
Pleural Drainage Catheters Market size was valued at USD billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 14.88% from 2024 to 2030. The Pleural Drainage Catheters Market is witnessing a significant surge, driven by a myriad of factors including the rising prevalence of respiratory disorders, advancements in catheter technology, and increasing demand for minimally invasive treatment options. This article explores the latest…
Global Pleural Effusion Drug Market - Industry Trends and Forecast to 2028
Global Pleural Effusion Drug Market - Industry Trends and Forecast to 2028
The pleural effusion drug market is expected to gain market growth at a potential rate of 4.70% in the forecast period of 2021 to 2028. Increase in prevalence rate of pleural effusion worldwide is the vital factor escalating the pleural effusion drug market growth.
Pleural effusion is a type of condition in which excessive fluids build-up or accumulates in the…
Malignant Pleural Effusions to Gain Maximum Traction in Pleural Catheters Market …
250 Pages Pleural Catheters Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider
According to Fact MR’s recent market research, sales of Pleural Catheters to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.
Focus on…
